The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Two-year Outcomes with the Cardioband Tricuspid System from the Multicentre, Prospective TRI-REPAIR Study

DOI: 10.4244/EIJ-D-20-01107

1. University Hospital Bonn, Bonn, Germany, Germany
2. Ludwig-Maximilians University Hospital Munich, Munich, Germany, Germany
3. University Medical Centre Mainz, Mainz, Germany, Germany
4. Marienkrankenhaus, Hamburg, Germany, Germany
5. Asklepios Klinik St. Georg, Hamburg, Germany, Germany
6. Hôpital Bichat-Claude Bernard, AP-HP, Paris, France,
7. Université Paris-Diderot, Paris, France,
8. INSERM U-1148, Paris, France, France
9. Montefiore Medical Center, Bronx, New York, USA, United States
10. IRCCS San Raffaele Scientific Institute, Milan, Italy, Italy
11. University Hospital Cologne, Cologne, Germany, Germany
12. Herz- und Diabeteszentrum NRW, Ruhr University of Bochum, Bad Oeynhausen, Germany, Germany
13. Edwards Lifesciences, Irvine, CA, USA, United States
14. Cardiovascular Research Foundation, New York, New York, USA, United States
15. University Hospital Zurich, Zurich, Switzerland, Switzerland
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

Aims: Tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options. We report one- and two-year outcomes of the Cardioband tricuspid valve reconstruction system in the treatment of ≥moderate functional TR in the TRI-REPAIR study.

Methods and results: Thirty patients were enrolled in this single-arm, multicentre, prospective study. Patients were evaluated to have ≥moderate, symptomatic functional TR and deemed inoperable due to unacceptable surgical risk. Clinical, functional, and echocardiographic data were prospectively collected up to two years (mean duration was 604 ± 227 days). At baseline, 83% were in NYHA Class III-IV, and mean LVEF was 58%. Technical success was 100%. At two years, there were eight deaths. Echocardiography showed significant reduction in septolateral annular diameter of 16% (p=0.006) and 72% of patients (p=0.016) with ≤moderate TR grade. 82% of patients were in NYHA Class I-II (p=0.002). Six-minute walk distance and KCCQ score improved by 73 m (p=0.058) and 14 points (p=0.046), respectively.

Conclusions: These results demonstrate that the Cardioband tricuspid system showed favourable results in patients with symptomatic, ≥moderate functional TR. Annular reduction and TR severity reduction remained significant and sustained at two years. Patients experienced improvements in quality of life and exercise capacity.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
A mini focus on bifurcation lesions including the Asia Pacific consensus document and a look at the double-kissing culotte technique; left atrial appendage closure compared to medical therapy; assessing aortic regurgitation using video-densitometry, a new classification for the BASILICA technique, and more…